淋巴结加量照射与MRI引导近距离放疗对淋巴结阳性宫颈癌肿瘤学结局的影响
这项前瞻性比较研究纳入161例淋巴结阳性、大块局部晚期宫颈癌患者,均接受根治性放化疗联合MRI引导近距离放疗;其中Boost组71例接受淋巴结加量至等效60 Gy,对照组90例未加量。中位随访36个月,Boost组3年区域控制率显著优于对照组(93% vs 80%,p=0.035),但无病生存与总生存无显著差异,急慢性毒性无显著差异。
要点
- 淋巴结加量照射可显著改善区域控制率(93% vs 80%,p=0.035)。
- 加量未显著改善无病生存(67.6% vs 58.9%,p=0.454)和总生存(78.9% vs 74.4%,p=0.87)。
- 加量未显著增加急性或晚期毒性。
核心结论
- 在标准治疗基础上加用外照射淋巴结加量可改善大块宫颈癌的盆腔控制,毒性可接受,但高全身失败率仍挑战生存改善。
研究设计与样本
- 前瞻性比较研究,纳入161例淋巴结阳性局部晚期宫颈癌患者,Boost组71例接受淋巴结加量至等效60 Gy,对照组90例未加量。
主要发现
- 中位随访36个月(IQR 19-50.5),总3年局部控制率为88.8%。
- Boost组3年区域控制率显著优于对照组(93% vs 80%,p=0.035)。
- 两组无病生存(67.6% vs 58.9%,p=0.454)和总生存(78.9% vs 74.4%,p=0.87)无显著差异。
- 淋巴结<3 cc且<2 cm者未见淋巴结失败,即使未加量组亦如此。
- 加量或加量技术未显著影响急慢性毒性发生率。
关键数值与推荐
- 所有患者至少一个肿瘤维度>5 cm,31%有腹主动脉旁淋巴结受累。
- 淋巴结加量等效剂量为60 Gy。
临床怎么用
- 对淋巴结阳性大块局部晚期宫颈癌,可考虑在标准放化疗联合MRI引导近距离放疗基础上加用淋巴结加量以改善区域控制。
- 加量未显著改善生存,需关注全身失败并探索系统性治疗策略。
局限性
- 对照组为历史对照,非随机同期对照。
- 样本量有限,随访时间中位36个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study aimed to prospectively evaluate the impact of dose-escalated irradiation of nodal metastases on clinical outcomes compared to no boost in patients with node-positive, bulky, locally advanced cervical cancer (LACC) undergoing standard chemoradiation and MRI-based brachytherapy. METHODS: This comparative study included 161 patients with node-positive LACC treated with definitive chemoradiation and MRI-based brachytherapy. The prospective Boost arm accrued 71 patients to receive nodal boost either sequentially or simultaneously to an equivalent dose of 60 Gy. The control arm comprised 90 patients treated before this protocol period with no additional nodal boost. RESULT: Baseline patient and tumor characteristics were similar in both groups. All patients had at least one tumor dimension >5 cm at presentation, and 31% had para-aortic node involvement. With a median follow-up of 36 months (IQR:19-50.5), the overall 3-year Local control rate was 88.8%. The 3-year Regional control (93% vs. 80%, p = 0.035) was statistically better in the Boost arm. No nodal failure was observed in nodes <3 cc and < 2 cm, even in the No-boost arm. There was no significant difference in Disease-free survival (67.6% vs. 58.9%,p = 0.454) and Overall Survival (78.9% vs. 74.4%,p = 0.87) between the two arms. Incidence of acute or late toxicities did not differ significantly with nodal boost or the boost delivery technique. CONCLUSION: The addition of external radiation nodal boost to standard treatment of high-volume cervical cancer has improved pelvic control with an acceptable rate of toxicities. However, high systemic failures continue to pose a challenge in improving survival outcomes.
引用
- Tiwari R, Narayanan GS, Reddy VP, et al. Impact of nodal boost irradiation and MR-based brachytherapy on oncologic outcomes in node-positive cervical cancer. Gynecol Oncol. 2021. PMID: 34304907. doi:10.1016/j.ygyno.2021.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。